AUTHOR INDEX

ABRASS, C.K. Evaluation of the presence of circulating immune complexes and their relationship to glomerular IgG deposits in streptozotocin-induced diabetic rats, 17

AGNELLI, A., *see* CASTES, M.

AGOSTINI, C., *see* SEMENZATO, G.

ALBERINI, C., *see* MACCARIO, R.

ALTOMARE, E., *see* DAMMACCO, F.

AMBROSETTI, A., *see* PIZZOLO, G.

AMOR, B., *see* MACH, P.S.

ANGI, M.R., *see* SEMENZATO, G.

ARANA, R., *see* BORDA, E.

BACON, T.H., OZBAKIR, F., ELMS, C.A. & DENMAN, A.M. Interferon-γ production by peripheral blood mononuclear cells from patients with Beçhet's syndrome, 541.

BAHR, G.M., MODABBER, F.Z., MORIN, A., TERRIER, M., EYQUEM, A. & CHEDID, L. Regulation by muramyl dipeptide (MDP) of the lymphoproliferative responses and polyclonal activation of human peripheral blood mononuclear cells, 178

BAKKEREN, J.A.J.M., *see* WEEMAES, C.M.R.

BALLESTRERO, A., *see* DALLEGRI, F.

BALTZ, M.L., CASPI, D., GLATTHAAR, B.E., MOSER, U. & PEPYS, M.B. The failure of ascorbic acid therapy to alter the induction or remission of murine amyloidosis, 657

BALTZ, M.L., *see* CASPI, D.

BARBIANO DI BELGIOJOSO, G., *see* COPPO, R.

BARTLETT, P.F., *see* BURNS, G.F.

BASOLO, B., *see* COPPO, R.

BAZELY, N., *see* MACH, P.S.

BAZIN, H., *see* PESTEL, J.

BENEDETTA DONATI, M., *see* VICENZI, E.

BERDEN, J.H.M., *see* LENS, J.W.

BIONDA, A., DE BAETS, M.H., TZARTOS, S.J., LINDSTROM, J.M., WEIGLE, W.O. & THEOPHILOPOULOS, A.N. Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis, 41

BIONDI, A., *see* VICENZI, E.

BIRD, P., *see* PARKES, A.B.

BLANC, C., *see* CAVAILLE-COLL, M.

BLASCO, R., *see* EGIDO, J.

BOFILL, M., *see* PIZZOLO, G.

BOJA, B., *see* KRESINA, T.

BONETTI, F., *see* MACCARIO, R.

BORDA, E., PASCUAL, J., COSSIO, P., DE LA VEGA, M., ARANA, R. & STERIN-BORDA, L. A circulating IgG in Chagas' disease which binds to β-adrenoceptors of myocardium and modulates their activity, 679

BORDIGNON, C., *see* VICENZI, E.

BOTTAZZO, G.F., *see* HANAFUSA, T.

BOUCHARD, P., *see* CHARREIRE, J.

BOUSHIRA, M., *see* WAINBERG, M.A.

BRANDTZAEG, P., *see* SCOTT, H.

BREEDVELD, F.C., LAFEBER, G.J.M., DE VRIES, E., DAHA, M.R. & CATS, A. C3 receptors on granulocytes from patients with rheumatoid arthritis and Felty's syndrome, 557

BREGMAN, V., *see* SCHATTNER, A.

BRENNER, M.B., *see* MAEDA, K.

BRISSON, E., *see* CAVAILLE-COLL, M.

BROSTOFF, J., *see* HUDSPITH, B.

BULMER, J.N. & JOHNSON, P.M. Macrophage populations in the human placenta and amniochorion, 393

BULZOMI, M.R., *see* COPPO, R.

BURGIO, G., *see* MACCARIO, R.

BURNS, G.F., GOOD, M.F., RIGLAR, C., BARTLEET, P.F., CRAPPER, R.M. & MACKAY, I.R. Activated lymphocyte killer cells derived from melanoma tissue or peripheral blood, 487.

BURRAI, I., *see* HENDERSON, B.

CAMPOBASSO, N., *see* DAMMACCO, F.

CAPRON, A., *see* PESTEL, J.

CAPRON, A., *see* PRIN, L.

CAPRON, M., *see* PRIN, L.

CARBONARA, A.O., *see* COPPO, R.

CARVALHO, G.S., *see* O'TOOLE, C.M.

CASPI, D., BALTA, M.L., FEINSTEIN, A., MUNN, E.A. & PEPYS, M.B. Amyloid degrading activity of human serum and *in vitro* clearing effect which does not involve degradation of amyloid fibrils, 647

CASPI, D., *see* BALTZ, M.

CASTÉS, M., AGNELLI, A. & RONDON, A. Mechanisms associated with immunoregulation in human American cutaneous leishmaniasis, 279

CATS, A., *see* BREEDVELD, F.C.

CAVAILLE-COLL, M., MESSIAH, A., KLATZMANN, D., ROSENBAUM, W., LACHIVER, D., KERNBAUM, S., BRISSON, E, CHAPUIS, F., BLANC, C., DEBRE, P. & GLUCKMAN, J.-C. Critical analysis of T cell subsets and functional evaluation in patients with persistent generalized lymphadenopathy in groups at risk for AIDS, 511

CHAPUIS, F., *see* CAVAILLE-COLL, M.

CHARON, J., *see* PRIN, L.

CHARREIRE, J., KARSENTY, G., BOUCHARD, P. & SCHAISON, G. Effect of carbimazole treatment on specific and non-specific immunological parameters in patients with Graves' disease, 663

CHEDID, L., *see* BAHR, G.M.

CHEN, Y.-H. & HELLER, P. Diffusible suppressor factor from splenic macrophages in murine plasmacytoma, 171

CHILOSI, M., *see* SEMENZATO, G.

CHILOSI, M., *see* PIZZOLO, G.

CHIOVATA, L., *see* HANAFUSA, T.

CIBODDO, G.F., *see* PARDI, R.

CIPRIANI, A., *see* SEMENZATO, G.

CLEMENT, D., *see* DE SCHEERDER, I.

CLIFTON, P.M., *see* DREW, P.A.

CLOSS, O., *see* LOVIK, M.

CLOSS, O., *see* REITAN, L.J.

COPPO, R., BASOLO, B., PICCOLI, G., MAZZUCCO, G., BULZOMI, M.R., ROCCATELLO, D., DE MARCHI, M., CARBONARA, A.O. & BARBIANO DI BELGIOJOSO, G. IgA1 and IgA2 immune

COPPO (*cont.*)
complexes in primary IgA nephropathy and Henoch–Schönlein nephritis, 583
COSSIO, P., *see* BORDA, E.
COX, J.C., *see* HENDERSON, B.
CRANAGE, M.P., *see* O'TOOLE, C.M.
CRANDALL, C.A., *see* JONES, J.F.
CRANDALL, R.B., *see* JONES, J.F.
CRAPPER, R.M., *see* BURNS, G.F.
CUNNINGHAM, J., *see* PENNING, C.A.
CURI, P.R., *see* DE ALMEIDA, D.B.
CURRAN, J.J., *see* TARTOF, D.

DAHA, M.R., *see* BREEDVELD, F.C.
DALLEGRI, F., PATRONE, F., BALLESTRERO, A., FRUMENTO, G. & SACCHETTI, C. Chemotactic peptide enhancement of PMA triggered monocyte cytotoxicity, 717
DAMMACCO, F., VACCA, A., ALTOMARE, E. & CAMPOBASSO, N. Immunoglobulin secretion by peripheral blood and bone marrow B cells in patients with multiple myeloma. Studies by the reverse haemolytic plaque assay, 743
DE ALMEIDA, D.B. & CURI, P.R. Treatment of rat nephrotoxic nephritis. Use of 5-fluorouracil or methotrexate-5-fluorouracil association, 591
DE ALMEIDA, M., *see* THYPHRONITIS, G.
DEAN, C.J., STYLES, J.M., GYURE, L.A., PEPPARD, J., HOBBS, S.M., JACKSON, E. & HALL, J.G. The production of hybridomas from the gut associated lymphoid tissue of tumour bearing rats. I. Mesenteric nodes as a source of IgG producing cells, 358
DEAN, C.J., *see* STYLES, J.M.
DE BAETS, M.H., *see* BIONDA, A.
DEBRE, P., *see* CAVAILLE-COLL, M.
DE LA VEGA, M., *see* BORDA, E.
DELPRE, G., *see* ILFELD, D.
DELVES, P.J. & ROITT, I.M. Idiotypic determinants on human thyroglobulin autoantibodies derived from the serum of Hashimoto patients and EB virus transformed cell lines, 33
DE MARCHI, M., *see* COPPO, R.
DENMAN, A.M., *see* BACON, T.H.
DEPLEDGE, P., *see* TAVERNE, J.
DEROM, F., *see* DE SCHEERDER, I.
DE SCHEERDER, I., WULFRANK, D, VAN RENTERGHEM, L., SABRE, L., ROBBRECHT, D., CLEMENT, D., DEROM, F., PLUM, J. & VERDONK, G. Association of anti-heart antibodies and circulating immune complexes in the post-pericardiotomy syndrome, 423
DESILVA, M.A., *see* MIZUSHIMA, Y.
DESSAINT, J.P., *see* PESTEL, J.
DE VRIES, E., *see* BREEDVELD, F.C.
DIENES, H.P., *see* MANNS, M.
DONIACH, D., *see* HANAFUSA, T.
DOOREN, L.J., *see* RÜMKE, H.C.
DOUGADOS, M., *see* MACH, P.S.
DREW, P.A., CLIFTON, P.M., LABROOY, J.T. & SHEARMAN, D.J.C. Polyclonal B cell activation in alcoholic patients with no evidence of liver dysfunction, 479
DREXHAGE, H.A., *see* WILDERS, M.M.

EGIDO, J., BLASCO, R., LOZANO, L., SANCHO, J. & GARCIA-HOYO, R. Immunological abnormalities in tonsils of patients with IgA nephropathy: inversion in the ratio of IgA:IgG bearing lymphocytes and increased polymeric IgA synthesis, 101
EK, J., *see* SCOTT, H.
ELMS, C.A., *see* BACON, T.H.
EMERY, P., PANAYI, G.S. & NOURI, A.M.E. Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis, 123
ENDOH, M, SUGA, T., MIURA, M., TOMINO, Y., NOMOTO, Y. & SAKAI, H. *In vivo* alteration of antibody production in patients with IgA nephropathy, 564
ENGERS, H.D., *see* LIMA, G.C.
EVANS, S.W., GREGSON, N.A., LEIBOWITZ, S.L. & LING, N.R. Investigation of the idiotypic determinants of IgM monoclonal proteins associated with neuropathy, 621
EYQUEM, A., *see* BAHR, G.M.

FARNDON, J.R., *see* WARFORD, A.
FAUCI, A.S., *see* GERRARD, T.L.
FAUSA, O., *see* SCOTT, H.
FEINSTEIN, A., *see* CASPI, D.
FERRERO, E., *see* PARDI, R.
FRAZER, I.H. & MACKAY, I.R. Antibodies to liver cell membrane antigens in chronic active hepatitis (CAH). III. Partial characterization of the liver cell membrane antigens and comparison of reactivities in sera from patients with various liver diseases, 429
FRENCH, M.A.H., *see* PENNING, C.A.
FRUMENTO, G., *see* DALLEGRI, F.
FUNAKI, H., *see* KOIKE, T.

GARCIA-HOYO, R., *see* EGIDO, J.
GASTL, G., *see* RUMPOLD, H.
GELSTHORPE, K., *see* REEVES, W.G.
GERRARD, T.L., JURGENSEN, C.H. & FAUCI, A.S. Modulation of human B cell responses by a monoclonal antibody to an activation antigen 4F2, 155
GIDLUND M., *see* D KABELITZ, D.
GLATTHAAR, B.E., *see* BALTZ, M.L.
GLUCKMAN, J.-C., *see* CAVAILLE-COLL, M.
GODAL, T., *see* SMELAND, E.B.
GOLDBERG, V., *see* KRESINA, T.
GOOD, M.F., *see* BURNS, G.F.
GOSSET, PH., *see* PRIN, L.
GOTOH, Y.-I., MINEGISHI, M., YAMAGUCHI, Y., KONNO, T & TADA, K. Interleukin-2 activated peripheral blood lymphocytes and the correlation of lytic activity and peanut agglutinin receptor expression on malignant cells, 710
GREGSON, N.A., *see* EVANS, S.W.
GYURE, L.A., *see* DEAN, C.J.
GYURE, L.A., *see* STYLES, J.M.

HAHN, T., *see* SCHATTNER, A.
HAKIM, J., *see* PERIANIN, A.
HALL, J.G., *see* DEAN, C.J.
HALL, J.G., *see* STYLES, J.M.
HANAFUSA, T., PUJOL-BORRELL, R., CHIOVATO, L., DONIACH, D. & BOTTAZZO, G.F. *In vitro* and *in vivo* reversal of thyroid epithelial polarity:

HANAFUSA (*cont.*)
its relevance for autoimmune thyroid disease, 638
HANSON, R.G., HOOFNAGLE, J.H., MINUK, G.Y., PURCELL, R.H. & GERIN, J.L. Cell-mediated immunity to hepatitis B surface antigen in man, 257
HARRISON, G., *see* PENNING, C.A.
HAUSER, C., WILHELM, J.A., MATTER, L. & SCHOPFER, K. Spontaneous and pokeweed mitogen-induced *in vitro* IgG production specific for *S. aureus* cell wall determinants in man, 227
HELLER, P., *see* CHEN, Y.-H.
HENDERSON, B., STAINES, N.A., BURRAI, I. & COX, J.H. The anti-arthritic and immunosuppressive effects of cyclosporine on arthritis induced in the rat by type II collagen, 51
HERMAN, J. & RABSON, A.R. prostaglandin E_2 depresses natural cytotoxicity by inhibiting interleukin-1 by large granular lymphocytes, 380
HERRMANN, F., *see* SEMENZATO, G.
HIRAHIMA, M., TASHIRO, K., SAKATA, K. & HIRASHIMA, M. Isolation of an eosinophil chemotactic lymphokine as a natural mediator for eosinophil chemotaxis from concanavalin A-induced skin reaction sites in guinea-pigs, 211
HIRASHIMA, M., *see* HIRASHIMA, M.
HIROFUJI, T., *see* KAKIMOTO, K.
HOBBS, S.M., *see* DEAN, C.J.
HOBBS, S.M., *see* STYLES, J.M.
HOLBOROW, E.J., *see* UNSWORTH, D.J.
HOOFNAGLE, J.H., *see* HANSON, R.G.
HOSKING, C.S., *see* PEREIRA, H.A.
HOWIE, S., *see* MCBRIDE, W.H.
HUBER, CH., *see* RUMPOLD, H.
HUDSPITH, B., BROSTOFF, J., MCNICOL, M.W. & JOHNSON, N.MCJ. Anergy in sarcoidosis: the role of interleukin-1 and prostaglandins in the depressed *in vitro* lymphocyte response, 324
HUGHES, P., *see* PENNING, C.A.
HYODO, S., KISHI, T., KASHIWA, H., KITTAKA, E., SUZAWA, T., TANAKA, T., SAKANO, T. & USUI, T. Effects of tunicamycin and various monosaccharides on phytohaemagglutinin-induced autorosette formation, 234

IESATO, S., *see* MORI, Y.
ILFELD, D., THEODOR, E., DELPRE, G. & KUPERMAN, O. *In vitro* correction of a deficiency of Con A-induced suppressor cell function in primary biliary cirrhosis by a pharmacological concentration of colchicine, 438
ILONEN, J., *see* RUUSKA, P.
IMHOF, J.W., *see* VAN DIJK, H.
INAGAKI, Y., MORIZANE, T., MATSUMURA, S., KAWAMURA, N., WATANABE, T., KUMAGAI, N., NAKAMURA, T., TSUCHIMOTO, K. & TSUCHIYA, M. Detection of antibodies to Chang liver cell in sera from patients with chronic liver diseases by ^{125}I-labelled protein A binding assay and the effect of prednisolone and 6-mercaptopurine treatment on the level of the antibodies, 79
INVERARDI, L., *see* PARDI, R.

JACKSON, E., *see* DEAN, C.J.
JANKOWSKI, I.G., *see* VAN DIJK, H.
JANOSSY, G., *see* PIZZOLO, G.
JEFFERIS, R., *see* SMELAND, E.B.
JEPSEN, S., *see* KHARAZMI, A.
JOHNSON, N.MCJ., *see* HUDSPITH, B.
JOHNSON, P.M., *see* BULMER, J.N.
JONES, J.F., CRANDALL, C.A. & CRANDALL, R.B. *In vivo* and *in vitro* responses to sheep erythrocytes by lymph nodes cells from mice with trichinellosis, 301
JOSEPH, M., *see* PESTEL, J.
JURGENSEN, C.H., *see* GERRARD, T.L.

KABELITZ, D., TOTTERMAN, T.H., NILSSON, K. & GIDLUND, M. Phorbol ester treated chronic B lymphocyte leukaemia cells induce autologous T cell proliferation without generation of cytotoxic T cells, 461
KAKIMOTO, K., HIROFUJI, T. & KOGA, T. Specificity of anti-type II collagen antibody response in rats, 57
KANOH, T., *see* YASUDA, N.
KARSENTY, G., *see* CHARREIRE, J.
KASHIWA, H., *see* HYODO, S.
KAWAMURA, N., *see* INAGAKI, Y.
KAY, A.B. & WALSH, G.M. Chemotactic factor-induced enhancement of the binding of human immunoglobulin classes and subclasses to neutrophils and eosinophils, 729
KERCKHAERT, J.A.M., *see* VAN DIJK, H.
KERNBAUM, S., *see* CAVAILLE-COLL, M.
KHARAZMI, A. & JEPSEN, S. Enhanced inhibition of *in vitro* multiplication of *Plasmodium falciparum* by stimulated human polymorphonuclear leucocytes, 287
KHAROUBY, M., *see* MACH, P.S.
KIHARA, I., *see* YAMAMOTO, K.
KISHI, T., *see* HYODO, S.
KITTAKA, E., *see* HYODO, S.
KLATZMANN, D., *see* CAVAILLE-COLL, M.
KOBAYASHI, S., *see* MAEDA, K.
KOGA, T., *see* KAKIMOTO, K.
KOIKE, T., MURUYAMA, N., FUNAKI, H., TOIOKA, H. & YOSHIDA, S. Specificity of mouse hybridoma antibodies to DNA. II. Phospholipid reactivity and biologically false positive serological test for syphilis, 345
KOKJÉ, M., *see* WILDERS, M.M.
KONO, D., *see* MAEDA, K.
KOSUNEN, T.U., *see* RUUTU, P.
KRAFT, D., *see* RUMPOLD, H.
KRESINA, T., ROSNER, I., GOLDBERG, V., BOJA, B. & MOSKOWITZ, R. IgA-induced experimental immune synovitis: hormonal modulation of *in vitro* splenic immune responses to homologous antigens, 63
KUMAGAI, N., *see* INAGAKI, Y.
KUPERMAN, O., *see* ILFELD, D.

LABROOY, J.T., *see* DREW, P.A.
LABRO-BRYSKIER, M.-T., *see* PERIANIN, A.
LACHIVER, D., *see* CAVAILLE-COLL, M.
LAFEBER, G.J.M., *see* BREEDVELD, F.C.

LAMPERT, I.A. Expression of HLA-DR (Ia like) antigen on epidermal keratinocytes in human dermatoses, 93
LAPPIN, D. & WHALEY, K. Adenosine A2 receptors on human monocytes modulate C2 production, 454
LARGE, S., *see* O'TOOLE, C.M.
LEGACE-SIMARD, J., *see* WAINBERG, M.A.
LEIBOWITZ, S.L., *see* EVANS, S.W.
LEID, R., SUQUET, C.M. & PERRYMAN, L.E. Inhibition of antigen- and lectin-induced proliferation of rat spleen cells by a *Taenia taeniaeformis* proteinase inhibitor, 187
LEMS, S.P.M., *see* LENS, J.W.
LENS, J.W., VAN DEN BERG, W.B., VAN DE PUTTE, L.B.A., BERDEN, J.H.M. & LEMS, S.P.M. Flare-up of antigen-induced arthritis in mice after challenge with intravenous antigen: effects of pre-treatment with cobra venom factor and anti-lymphocyte serum, 520
LEVIN, S., *see* SCHATTNER, A.
LEW, A.M., STAINES, N.A. & STEWARD, M.W. Glomerulonephritis induced by pre-formed immune complexes containing monoclonal antibodies of defined affinity and isotype, 413
LIMA, G.C., ENGERS, H.D. & LOUIS, J.A. Adoptive transfer of delayed type hypersensitivity reactions specific for *Leishmania major* antigens to normal mice using murine T cell populations and clones generated *in vitro*, 130
LINDSTROM, J.M., *see* BIONDA, A.
LING, N.R., *see* EVANS, S.W.
LIVINGSTON, C., *see* TARTOF, D.
LOUIS, J.A., *see* LIMA, G.C.
LOVIK, M. & CLOSS, O. Survival of *Mycobacterium lepraemurium* in C57BL mice after acquired protective immunity, 115
LOZANO, L., *see* EGIDO, J.
LUTCHER, F., *see* MACH, P.S.

MACARIO, R., UGAZIO, A., NESPOLI, L., ALBERINI, C., MONTAGNA, D. PORTA, F., BONETTI, F. & BURGIO, G. Lymphocyte subpopulations in Down's syndrome: high percentage of circulating HNK-1$^+$, Leu 2a$^+$ cells, 220
MACH, P.S., KHAROUBY, M, TUTCHER, F., OLIVIER, J.L., BAZELY, N., DOUGAGADOS, M. & AMOR, B. The *in vitro* production of anti-nuclear antibodies by human peripheral blood mononuclear cells. Demonstration of T cell requirement and soluble inducing factor(s) for anti-nuclear antibodies triggering in patients with systemic lupus erythematosus, 535
MACKAY, I.R., *see* BURNS, G.F.
MACKAY, I.R., *see* FRAZER, I.H.
MAEDA, K., KONO, D., KOBAYASHI, S., BRENNER, M.B. & YU, D.T.Y. A study of the specificity of the direct binding between bacteria and HLA antigens, 694
MALCOLM, A.J., *see* WARFORD, A.
MANNS, M., MEYER ZUM BUSCHENFELD, K.-H., SLUSARCZYK, J. & DIENES, H.P. Detection of liver–kidney microsomal autoantibodies by radioimmunoassay and their relation to anti-mitochondrial antibodies in inflammatory liver diseases, 600
MANTOVANI, A., *see* VICENZI, E.
MARGOLESE, R.G., *see* WAINBERG, M.A.
MARLISS, E.B., *see* YALE, J.-F.
MARQUETTY, C., *see* PERIANIN, A.
MARUYAMA, N., *see* KOIKE, T.
MATSUMURA, S., *see* INAGAKI, Y.
MATTER, L., *see* HAUSER, C.
MATTHEWS, N, *see* TAVERNE, J.
MAURY, C.P.J., *see* TEPPO. A.-M.
MAZZUCCO, G., *see* COPPO, R.
MCBRIDE, W.H. & HOWIE, S. Paradoxical presence of T cell anergy during successful T cell-dependent tumour immunotherapy: characterization of a state of T cell 'amnaesia' following systemic administration of *C. parvum*, 139
MCLACHLAN, S.M., *see* WARFORD, A.
MCLACHLAN, S.M., *see* PARKES, A.B.
MCNICOL, M.W., *see* HUDSPITH, B.
MENDELSON, J., *see* WAINBERG, M.A.
MERLIN, G., *see* SCHATTNER, A.
MESSIAH, A., *see* CAVAILLE-COLL, M.
MEUWISSEN, S.G.M., *see* WILDERS, M.M.
MEYER ZUM BÜSCHENFELD, K.-H., *see* MANNS, M.
MILLER, C., *see* RUSSELL, A.S.
MILLS, K.H.G., *see* SEMENZATO, G.
MINEGISHI, M., *see* GOTOH, Y.-H.
MINUK, G.Y., *see* HANSON, R.G.
MIURA, M., *see* ENDOH, M.
MIZUSHIMA, Y., WEPSIC, H.T., YAMAMURA, Y. & DESILVA, M.A. Tumour-induced suppressor macrophages in rats: differences in their suppressive effects on the Con A and PHA responses, 371
MODABBER, F.Z., *see* BAHR, G.M.
MONTAGNA, D., *see* MACCARIO, R.
MORI, T., *see* MORI, Y.
MORI, Y., MORI, T., YOSHIDA, H., UEDA, S., IESATO, S., WAKASHIN, Y., WAKASHIN, M. & OKUDA, K. Study of cellular immunity in experimental autoimmune hepatitis in mice, 85
MORIN, A., *see* BAHR, G.M.
MORITTU, L., *see* SEMENZATO, G.
MORITTU, L., *see* PIZZOLO, G.
MORIZANE, T., *see* INAGAKI, Y.
MOSER, U., *see* BALTZ, M.L.
MOSKOWITZ, R., *see* KRESINA, T.
MUNN, E.A., *see* CASPI, D.
MURDOCH, R.D. & PEPYS, J. Immunological responses to complex salts of platinum. I. Specific IgE antibody production in the rat, 107
MUSTONEN, A., *see* RUUSKA, P.

NAKAMURA, T., *see* INAGAKI, Y.
NAKASHIMA, S., *see* RUSSELL, A.S.
NESPOLI, L., *see* MACCARIO, R.
NEVEU, T., *see* THYPHRONITIS, G.
NILSSON, K., *see* KABELITZ, D.
NOMOTO, Y., *see* ENDOH, M.
NOURI, A.M.E., *see* EMERY, P.

O'TOOLE, C.M., CARVALHO, G.S., CRANGE, M.P. & LARGE, S. Immune responses in cardiac transplantation. I. Detection of activated TIa$^+$ cells in the blood during herpes virus infections, 671
OITE, T., *see* YAMAMOTO, K.

OKUDA, K., *see* MORI, Y.
OLIVIER, J.L., *see* MACH, P.S.
OSSI, E., *see* SEMENZATO, G.
OZBAKIR, F., *see* BACON, T.H.

PANAYI, G.S., *see* EMERY, P.
PARDI, R., ZOCCHI, M.R., FERRERO, E.,CIBODDO, G.F., INVERARDI, L. & RUGARLI, C. *In vivo* effects of a single infusion of theophylline on human peripheral blood lymphocytes, 722
PARKES, A.B., MCLACHLN, S.M., BIRD, P. & REES SMITH, B. The distribution of microsomal and thyroglobulin activity among the IgG subclasses, 239
PASCUAL, J., *see* BORDA, E.
PATRONE, F., *see* DALLEGRI, F.
PENNING, C.A., CUNNINGHAM, J., FRENCH, M.A.H., HARRISON, G., ROWELL, N.R. & HUGHES, P. Antibody-dependent cellular cytotoxicity of human vascular endotheliumin in systemic sclerosis, 548
PEPPARD, J., *see* DEAN, C.J.
PEPYS, J., *see* MURDOCH, R.D.
PEPYS, M.B. 2, *see* BALTZ, M.L.
PEPYS, M.B. 2, *see* CASPI, D.
PEREIRA, H.A. & HOSKING, C.S. The role of complement and antibody in opsonization and intracellular killing of *Candida albicans*, 307
PERIANIN, A., LABRO-BRYSKIER, M.-T., MARQUETTY, C. & HAKIM, J. Glutathione reductase and nitroblue tetrazolium reduction deficiencies in neutrophils of patients with primary idiopathic myelofibrosis, 244
PERRYMAN, L.E., *see* LEID, R.
PESTEL, J., DESSAINT, J.P., JOSEPH, M., BAZIN, H. & CAPRON, A. Macrophage triggering by aggregated immunoglobulins. II. Comparison of IgE and IgG aggregates or immune complexes, 404
PETERS, T.J., *see* SHAH, T.
PICCOLI, G., *see* COPPO, R.
PIZZOLO, G., *see* SEMENZATO, G.
PIZZOLO, G., SEMENZATO, G., CHILOSI, M., MORITTU, L., AMBROSETTI, A., WARNER, N, BOFILL, M. & JANOSSY, G. Distribution and heterogeneity of cells detected by HNK-1 monoclonal antibody in blood and tissues in normal, reactive and neoplastic conditions, 195
PLAYFAIR, J.H.L., *see* TAVERNE, J.
PLUM, J., *see* DE SCHEERDER, I.
PORTA, F., *see* MACCARIO, R.
PRIN, L., CHARON, J., CAPRON, M., GOSSET, PH., TAELMAN, H., TONNEL, A.B. & CAPRON, A. Heterogeneity of human eosinophils. II. Variability of respiratory burst activity related to cell density, 735
PUFOL-BORRELL, R., *see* HANAFUSA, T.
PURCELL, R.H., *see* HANSON, R.G.

RABSON, A.R., *see* HERMAN, J.
RAMBALDI, S., *see* VICENZI, E.
REES SMITH, B., *see* WARFORD, A.
REES SMITH, B., *see* PARKES, A.B.
REEVES, W.G., GELSTHORPE, K., VAN DER MINNE, P., TORENSMA, R. & TATTERSALL, R.B. HLA phenotype and insulin antibody, 443
REITAN, L.J. & CLOSS, O. *In vitro* stimulation of lymphocytes with an antigen fraction prepared from *Mycobacterium leprae* and tuberculin PPD in contacts and non-contacts of leprosy patients, 315
REPO, H., *see* RUUTU, P.
REVEL, M., *see* SCHATTNER, A.
RIGLAR, C., *see* BURNS, G.F.
ROBBRECHT, D., *see* DE SCHEERDER, I.
ROCATELLO, D., *see* COPPO, R.
ROITT, I.M., *see* DELVES, P.J.
RONDÓN, A., *see* CASTÉS, M.
ROOS, M.TH.L., *see* RÜMKE, H.C.
ROSNER, I., *see* KRESINA, T.
ROWELL, N.R., *see* PENNING, C.A.
ROZENBAUM, W., *see* CAVAILLE-COLL, M.
RUGARLI, C., *see* PARDI, R.
RÜMKE, H.C., TERPSTRA, F.G., ROOS, M.TH.L., VOSSEN, J.M., DOOREN, L.J., SCHELLEKENS, P.TH.A. & ZEIJLEMAKER, W.P. Bone marrow transplantation in man. Analysis of T and B cell functions in PWM driven Ig production, 467
RUMPOLD, H., KRAFT, D., GASTL, G. & HUBER, CH. The relationship of HNK-1 (Leu 7) and VEP13 antigens on human cells mediating natural killing, 703
RUSSELL, A.S., NAKASHIMA, S. & MILLAR, C. *In vitro* boost of human NK activity by a triethylphospine gold derivative, 207
RUUSKA, P., ILONEN, J, MUSTONEN, A. & TIILIKAINEN, A. Defective erythrocyte C3b receptor function associated with low serun complement (C3,C4) concentrations in insulin-dependent diabetes mellitus, 12
RUUTU, P., SAVILAHTI, E., REPO, H. & KOSUNEN, T.U. Constant defect in neutrophil locomotion but with age decreasing susceptibility to infection in Shwachman syndrome, 249

SABRE, L., *see* DE SCHEERDER, I.
SACCHETTI, C., *see* DALLEGRI, F.
SAKAI, H., *see* ENDOH, M.
SAKANO, T., *see* HYODO, S.
SAKATA, K., *see* HIRASHIMA, M.
SANCHO, J., *see* EGIDO, J.
SAVILAHTI, P., *see* RUUTU, P.
SCHAISON, G., *see* CHARREIRE, J.
SCHATTNER, A., MERLIN, G., BREGMAN, V., HAHN, T., LEVIN S., REVEL, M. & WALLACH, D. (2′–5′) oligo A synthetase in human polymorphonuclear cells increased activity in interferon treatment and in viral infections, 265
SCHELLEKENS, P.TH.A., *see* RÜMKE, H.C.
SCHNEIDER, H. & URBANEK, R. Humoral and cellular immune response of the rat to immunization with bee venom, 449
SCHOPFER, K., *see* HAUSER, C.
SCHOT, L.P.C., VERHEUL, H.A.M. & SCHUURS, A.H.W.M. Effect of nandrolone decanoate on Sjogren's syndrome like disorders in NZB/NZW mice, 571
SCHUURS, A.H.W.M., *see* SCHOT, L.P.C.
SCOTT, D.L., *see* UNSWORTH, D.J.

SCOTT, H., FAUSA, O, EK, J. & BRANDTZAEG, P. Immune response patterns in coeliac disease. Serum antibodies to dietary antigens measured by an enzyme linked immunosorbent assay (ELISA), 25
SEMENZATO, G., AGOSTINI, C. TRENTIN, L., ZAMBELLO, M., CHILOSI, M., CIPRIANI, A., OSSI, E., ANGI, M.R., MORITTU, L. & PIZZOLO Evidence of cells bearing interleukin-2 receptor at sites of disease activity in sarcoid patients, 331
SEMENZATO, G., HERRMENN, F. & MILLS, K.H.G. *Letter to the Editor* T cell subpopulations in B cell chronic lymphocytic leukaemias, 752
SEMENZATO, G., *see* PIZZOLO, G.
SHAH, T., WEBSTER, A.D.B. & PETERS, T.J. Kinetic properties of 5'nucleotidase in blood lymphocytes from healthy subjects, immunodeficient patients and cord blood, 149
SHEARMAN, D.J.C., *see* DREW, P.A.
SHIMADA, H., *see* YASUDA, N.
SHIMIZU, F., *see* YAMAMOTO, K.
SHIRATSUCHI, H. & TSUYUGUCHI, I. Analysis of T cell subsets by monoclonal antibodies in patients with tuberculosis after *in vitro* stimulation with purified protein derivative of tuberculin, 271
SLUSARCZYK, J., *see* MANNS, M.
SMELAND, E.B., JEFFEREIS, R. & GODAL, T. Surface IgG subclasses in human B cell lymphomas as revealed by monoclonal antibodies, 163
SPIRA, B., *see* WAINBERG, M.A.
STAINES, N.A., *see* HENDERSON, B.
STAINES, N.A., *see* LEW, A.M.
STERIN-BORDA, L., *see* BORDA, E.
STEWARD, M.W., *see* LEW, A.M.
STYLES, J.M., DEAN, C.J., GYURE, L.A., HOBBS, S.M. & HALL, J.G. The production of hybridomas from the gut associated lymphoid tissue of tumour bearing rats. II. Peripheral intestinal lymph as a source of IgA producing cells, 365
STYLES, J.M., *see* DEAN, C.J.
SUGA, T., *see* ENDOH, M.
SUQUET, C.M., *see* LEID, R.
SUZAWA, T., *see* HYODO, S.

TADA, K., *see* GOTOH, U.-H.
TAELMAN, H., *see* PRIN, L.
TANAKA, Y., *see* HYODO, S.
TARTOF, D., CURRAN, J.J., YANG, S.L. & LIVINGSTON, C. NK cell activity and skin test antigen stimulation of NK like CMC *in vitro* are decreased to different degrees in pregnancy and sarcoidosis, 502
TASHIRO, K., *see* HIRASHIMA, M.
TATTERSALL, R.B., *see* REEVES, W.G.
TAVERNE, J., MATTHEWS, N., DEPLEDGE, P. & PLAYFAIR, J.H.L. Malarial parasites and tumour cells are killed by the same component if tumour necrosis serum, 293
TEPPO,, A.-M. & MAURY. C.P.J. Antibodies to gliandid, gluten and reticulin glycoprotein in rheumatic diseases: elevated levels in Sjögren's syndrome, 73
TERPSTRA, F.G., *see* RÜMKE, H.C.
TERRIER, M., *see* BAHR, G.M.
THE, T.H., *see* WEEMAES, C.M.R.
THEODOR, E., *see* ILFELD, D.
THEOPHILOPOULOS, A.N., *see* BIONDA, A.
THYPHRONITIS, G., ALMEIDA, M., NEVEU, T. & VOISIN, G. GPLA antigens are not expressed on guinea-pig epididymal spermatozoa, 687
TIILIKAINEN, A., *see* RUUSKA, P.
TOMOIKA, H., *see* KOIKE, T.
TOMINO, Y., *see* ENDOH, M.
TONNEL, A.B., *see* PRIN, L.
TORENSMA, R., *see* REEVES, W.G.
TOTTERMAN, T.H., *see* KABELITZ, D.
TRENTIN, L., *see* SEMENZATO, G.
TSUCHIMOTO, K., *see* INAGAKI, Y.
TSUCHIYA, M., *see* INAGAKI, Y.
TSUYUGUCHI, I., *see* SHIRATSUCHI, H.
TZARTOS, S.J., *see* BIONDA, A.

UCHINO, H., *see* YASUA, N.
UEDA, S., *see* MORI, Y.
UGAZIO, A., *see* MACCARIO, R.
UNSWORTH, D.J., SCOTT, D.L., WALTON, K.W., WALKER-SMITH, J.A. & HOLBOROW, E.J. Failure of R1 type anti-reticulin antibody to react with fibronectin, collagen type III or the non-collagenous reticulin component (NCRC), 609
URBANEK, R., *see* SCHNEIDER, H.
USUI, T., *see* HYODO, S.

VACCA, A., *see* DAMMACCO, F.
VAN DEN BERG, W.B., *see* LENS, J.W.
VAN DE PUTTE, L.B.A., *see* LENS, J.W.
VAN DER MINNE, P., *see* REEVES, W.G.
VAN DIJK, H., VAN VOORST, J., JANKOWSKI, I.G., IMHOF, J.W. & KERCHAERT, J.A.M. Differential precipitation of the C1q subcomponent of the first complement component (C1) by polyethyleneglycol from normal human serum and sera of patients with collagen diseases, 495
VAN MUNSTER, P.J.J., *see* WEEMAES, C.M.R.
VAN RENTERGHEM, L., *see* DE SCHEERDER, I.
VAN VOORST, J., *see* VAN DIJK, H.
VERDONK, G., *see* DE SCHEERDER, I.
VERHEUL, H.A.M., *see* SCHOT, L.P.C.
VERSPAGET, H.W., *see* WILDERS, M.M.
VICENZI, E., BIONDI, A., BORDIGNON, C., RAMBALDI, A., BENEDETTA DONATIC, M. & MANTOVANI, A. Human mononuclear phagocytes from different anatomical sites differ in their capacity to metabolize arachidonic acid, 385
VOISIN, G., *see* THYPHRONITIS, G.
VOSSEN, J.M., *see* RÜMKE, H.C.
VYDELINGUM, S., *see* WAINBERG, M.A.

WAINBERG, M., VYDELINGUM, S., BOUSHIRA, M., LEGACE-SIMARD, J., MARGOLESE, R.G., SPIRA, B. & MENDELSON, J. Reversible interference with TCGF activity by virus particles, 663
WAKASHIN, M., *see* MORI, Y.
WAKASHIN, Y., *see* MORI, Y.
WALKER-SMITH, J.A., *see* UNSWORTH, D.J.
WALLACH, D., *see* SCHATTNER, A.
WALSH, G.M., *see* KAY, A.B.
WALTON, K.W., *see* UNSWORTH, D.J.
WARFORD, MCLACHLAN, S.M., MALCOLM, A.J., YOUNG, E.T., FARNDON, J.R. & REES SMITH, B. Characterization of lymphoid cells in the thyroid of patients with Graves' disease, 626

WARNER, N., *see* PIZZOLO, G.
WATANABE, T., *see* INAGAKI, Y.
WEBSTER, A.D.B., *see* SHAH, T.
WEEMAES, C.M.R., THE, T.H., VAN MUNSTER, P.J. & BAKKEREN, J.A.J.M. Antibody responses *in vivo* in chromosome instability syndromes with immunodeficiency, 529
WEIGLE, W.O., *see* BIONDA, A.
WEPSIC, H.T., *see* MIZUSHIMA, Y.
WHALEY, K., *see* LAPPIN, D.
WILDERS, M.M., DREXHAGE, H.A., KOKJE, M., VERSPAGET, H.W. & MEUWISSEN, S.G.M. Peripolesis followed by cytotoxicty in chronic idiopathic inflammatory bowel disease, 614
WILHELM, J.A., *see* HAUSER, C.
WULFRANK, D., *see* DE SCHEERDER, I.

YALE, J.-E. & MARLISS, E.B. Review: Altered immunity and diabetes in the BB rats, 1
YAMAGUCHI, Y., *see* GOTOH, Y.-H.
YAMAMOTO, K., OITE, T., KIHARA, I. & SHIMIZU, F. Experimental glomerulonephritis induced by human IgG in rats, 575
YAMAMURA, Y., *see* MIZUSHIMA, Y.
YANG, S.L., *see* TARTOF, D.
YASUDA, N., SHIMADA, H., KANOH, T. & UCHINO, H. J. chain synthesis and ultrastructural changes in chronic lymphocytic leukamia cells during *in vitro* differentitation, 351
YOSHIDA, H., , *see* MORI, Y.
YOSHIDA, S., *see* KOIKE, T.
YOUNG, E.T., *see* WARFORD, A.
YU, D.T.Y., *see* MAEDA, K.

ZAMBELLO, R., *see* SEMENZATO, G.
ZEIJLEMAKER, W.P., *see* RÜMKE, H.C.
ZOCCHI, M.R., *see* PARDI, R.

SUBJECT INDEX

^{125}I-labelled protein A assay, 79
2–5A synthetase, 265
4F2, 155
5′ nucleotidase, 149
5-fluorouracil, 591
6-mercaptopurine treatment, 79

AA amyloidosis, 647
ADCC
  systemic sclerosis, 548
  triggering, 404
Acquired immune deficiency syndrome, 511
Activated lymphocyte killer, 487
Activation antigen, 155
Alcohol, 479
Altered immunity, 1
American cutaneous leishmaniasis, 279
Aminophylline, 722
Amniochorion, 393
Amyloid degrading activity, 647
Amyloid fibrils, 647
Amyloidosis, murine, 657
Animal models, 107
Anti-adrenoceptor IgG, 679
Anti-lymphocyte serum, 520
Antibodies
  affinity, 413
  anti-DNA, 338
  anti-heart, 423
  anti-nuclear, 535
  anti-reticulin, 679
  insulin, 443
  microsomal, 239
  production, 564
  thyroid stimulating, 633
Antigens
  dietary, 25
  GPLA, 687
  hepatitis B surface, 257
  'microvillar', 639
  rheumatoid arthritis, 187
  spleen cell proliferation, 123
  spermatozoa, 687
Arachidonic acid metabolism, 385
Arthritis
  antibody specificity, 57
  antigen-induced, 520
  cyclosporine, 51
Ascorbic acid, 657
Auranofin, 207
Autoantibodies
  chronic active hepatitis, 429
  epididymal spermatozoa, 687
  liver-kidney microsomal, 600
  thyroglobulin, 33
Autoimmune diseases
  AChR antibodies, 41
  IFN-γ production, 51
  cyclosporine, 541
Autoimmunity
  antibody specificity, 57
  autoantibodies, 600
  IgG subclasses, 239
  liver diseases, 429
Autologous mixed leucocyte reaction, 461

B cells
  activation, 227
  responses, 155
BB rats, 1
BFP-STS, 345
Bacillary survival, 115
Bacteria, 687
Bacterial infection, 227
Beçhet's syndrome, 541
Bee venom, 449
Bone marrow transplantation, 467

C1q precipitation, 495
C2 synthesis, 454
C3 receptors, 557
C57BL mice, 115
Candida albicans, 307
Carbimazole, 633
Cardiac surgery, 423
Cardiolipin, 345
Cell-mediated immunity, 123
Cellular immunity
  autoimmune hepatitis, 85
  HLA-DR expression, 93
  immunoregulation, 279
Cellular response, 449
Cestodes, 187
Chagas' disease, 679
Chang liver cell, 79
Chemotactic factors
  Ig binding, 729
  monocyte cytotoxicity, 717
Chemotaxis
  Shwachman syndrome, 249
  lymphokine isolation, 211
Chromosome instability, 529
Chronic hepatitis, 257
Chronic liver disease, 79
Chronic lymphocytic leukaemia
  differentiation, 351
  proliferation, 461
Cobra venom factor, 520
Coeliac disease
  antibodies, 73
  immune response, 25
Colchicine, 438
Collagen type II
  antibody specificity, 57
  induced arthritis, 51
Collagen type III, 609
Common variable hypogammaglobulinaemia, 149
Complement
  C1q subcomponent, 495
  components, 12
Concanavalin A
  skin reaction, 211
  suppressor macrophages, 371
Congenital thymic derangement, 220
Corynebacterium parvum, 139
Cross-reactive idiotypes, 621
Cyclic AMP, 722
Cyclosporine, 51
Cytotoxicity
  bowel disease, 614

Cytotoxicity (*cont.*)
lymphocytes, 710
monocytes, 717

DR$^+$ thyrocytes, 626
Delayed hypersensitivity, 257
Delayed type hypersensitivity, 130
Density heterogeneity, 735
Diabetes mellitus
BB rats, 1
IgG deposits, 17
insulin-dependent, 12
Diabetic nephropathy, 17
Dihydroalprenolol binding, 679
Disease activity sites, 331
Down's syndrome, 220

EDTA, 85
ELISA, 25
Endothelium, human, 548
Eosinophils
blood, 735
chemotaxis, 211
immunoglobulin binding, 729
tissue, 735
Epstein–Barr virus, 33
Experimental hepatitis, 85

Felty's syndrome, 557
Fibronectin, 609
Flare-up reactions, 520
Follicles, reconstituted, 639

Gliadin, 73
Glomerulonephritis
experimental, 575
immune response, 413
Glutathione reductase, 244
Gluten
immune response, 25
sensitive enteropathy, 609
Glycoprotein, 234
Grave's disease
carbimazole, 633
lymphoid cells, 626
Growth, 287
Guinea-pigs
alloantigens, 687
MHC, 687
Gut associated lymphoid tissue
I, 358
II, 365

HLA
antigens, 687
diabetes mellitus, 12
phenotype, 443
HLA-DR, 93
HLA-DR positive cells, 614
HNK-1
cell detection, 195
natural killer cells, 703
Haemocyanin, 443
Haemolytic plaque assay, 743
Henoch–Schönlein nephritis, 583
Hepatitis, chronic, 600
Hepatitis liver cell membranes, 429
Hepatitis B virus vaccine, 257
Herpes virus, 663
Hofbauer cells, 393
Homosexuals, 511
Hormonal modulation, 63
Hybridomas
I, 358
II, 365
Hypersensitivity, local, 520

Idiotypes
leukaemia, 351
myasthenia gravis, 41
IgA
liver dysfunction, 479
nephropathy
antibody production, 564
immunological abnormalities, 101
polymeric, 101
primary nephropathy, 583
production, 365
IgE
IgA nephropathy, 107
macrophage triggering, 404
IgG
human, 575
liver dysfunction, 479
macrophage triggering, 404
mesenteric nodes, 358
subclasses
activity distribution, 239
surface, 163
synthesis, 27
Immune abnormalities, 101
Immune complexes
circulating
IgG deposits, 17
PPS, 423
collagen disease, 495
glomerulonephritis
experimental, 575
pre-formed, 413
leishmaniasis, 279
macrophage triggering, 404
nephritis, 583
Immune response
antibody, 529
splenic, 63
Immunization, 301
Immunodeficiency, 529
Immunoelectron microscopy, 351
Immunogenicity, 443
Immunoglobulins
cellular binding, 729
dietary antigens, 25
idiotypes, 33
production, 467
Immunohistology, 195
Immunomodulation, 722
Immunoregulation
leishmaniasis, 279
S. aureus cell wall, 227
Immunosuppression, 671

Immunosuppressive agents, 438
Immunotherapy, 139
Inflammation, 211
Inflammatory bowel disease, chronic idiopathic, 614
Insulin, 443
Interferon
  (2′–5′) oligo A synthetase, 265
  Down's syndrome, 220
  production, 541
Interleukin-1
  cytotoxicity, 380
  rheumatoid arthritis, 123
  sarcoidosis, 324
Interleukin-2
  lymphocyte activation, 710
  rheumatoid arthritis, 123
Intracellular killing, 307
Isoelectric focusing, 41
Isotype, 413

J chain, 351

Keratinocytes, 93

Lectin, 187
Leishmania major, 130
Leprosy, 315
Leu 7, 195
Leukaemia, B cell chronic lymphocytic, 752
Liver
  cirrhosis, 438
  disease, 479
  membrane, 429
  specific lipoprotein, 85
  specific protein
    hepatitis, 429
    liver diseases, 79
Lymphadenopathy, 511
Lymphocytes
  proliferation, 187
  stimulation, 315
  subpopulations, 722
  TCGF activity, 663
Lymphokines, 211
Lymphomas, 163

Macrophages
  activation, 404
  populations, 393
  splenic, 171
Malarial parasites, 293
Massive cutaneous hyalinosis, 73
Melanoma, 487
Methotrexate-5-fluorouracil, 591
Monoclonal antibodies
  4F2, 155
  anti-DNA, 345
  anti-Tac, 331
  B cell lymphomas, 163
  glomerulonephritis, 413
  HNK-1, 195
  myasthenia gravis, 41
  neuropathy, 621
  T cell subsets, 271
Monoclonal gammopathy, 743

Monocytes
  C2 production, 454
  cytotoxicity, 717
  sarcoidosis, 324
Mononuclear phagocytes, human, 385
Monosaccharide, 234
Multiple myeloma, 743
Multiple sclerosis, 265
Muramyl dipeptide, 178
Mycobacterium leprae, 315
Mycobacterium lepraemurium, 115
Myocardium activity, 679
Mysthenia gravis, 41

NZB/W mice, 571
Nandrolone decanoate, 571
Natural killer cells
  activity, 502
  antigens, 703
  Down's syndrome, 220
  HNK-1, 195
  PGE_2, 380
  triethylphosphine gold, 207
Nephrotoxic nephritis, 591
Neuropathy, 621
Neutrophils
  enzyme deficiencies, 244
  immunoglobulin binding, 729
  iodination, 307
  locomotion defect, 249
Nitroblue tetrazolium reduction, 244
Non-collagenous reticulin component, 609

Opsonization, 307
Oxidative burst, 287
Oxidative metabolism, 735

Pancreatic insufficiency, 249
Parasite infection, 301
Pathogenesis, 583
Peanut agglutinin, 710
Peripolesis, 614
Phagocytosis, 287
Phase contrast cinematography, 614
Phorbol ester, 461
Phytohaemagglutinin, 371
Placenta, human, 393
Plasma membrane, 149
Plasmacytoma, 171
Plasmodium falciparum, 287
Platinum, 107
Pokeweed mitogen, 467
Polarity inversion, 639
Polyclonal activation, 178
Polyethylene glycol, 495
Polymorphonuclear cells, 265
Polymorphonuclear leucocytes, 287
Post-pericardiotomy syndrome, 423
Pre-T lymphocytes, 220
Prednisolone, 79
Pregnancy, 502
Primary biliary cirrhosis, 438
Primary idiopathic myelofibrosis, 244
Primary immunization, 449
Proliferative response, 178

Prostaglandin E2, 380
Prostaglandins, 324
Protective immunity, 115
Proteinase inhibitor, 187

Radioimmunoassay, 600
Rat, 187
Reactive systemic amyloidosis, 647
Receptors
  A2, 454
  autorosette, 234
  C3b, 12
  immunoglobulin, 729
  interleukin-2, 331
Regulation, 178
Reticulin glycoprotein, 73
Retrovirus, 663
Rheumatoid arthritis
  C3 receptors, 557
  immune responses, 123

Sarcoidosis
  active, 331
  anergy, 324
  NK cell activity, 502
Sensitivity, 371
Serum albumin, 647
Sheep erythrocytes, 301
Shwachman syndrome, 249
Sjögren's syndrome
  antibody levels, 73
  nandrolone decanoate effects, 571
Spontaneously hypertensive rats, 575
Staphylococcus aureus, 227
Subpopulations, 735
Suppressor cells
  biliary cirrhosis, 438
  leishmaniasis, 279
Suppressor factor, 171
Suppressor macrophages, 371
Synovitis, 63
Systemic antigen administration, 520
Systemic lupus erythematosus
  anti-dsDNA antibodies, 338
  mononuclear cells, 535
  murine hybridomas, 345
Systemic sclerosis, 548

T cells
  anergy, 139
  clones, 130
  parasite immune, 130
  subpopulations, 752
  subsets
    carbimazole effects, 633
    monoclonal antibodies, 271
T helper cells, 467
T lymphocytes, 511
T suppressor cells, 467
TCGF
  T cell anergy, 139
  activity interference, 663
TIa$^+$ cells, 671
Thyroglobulin
  autoantibodies, 33
  IgG distribution, 239
Thyroid, 239
Thyroid cell culture, human, 633
Thyroid lymphocytes, 626
Thyroiditis, autoimmune, 639
Tonsils, 101
Trichinella spiralis, 301
Triethyl-phosphine gold, 207
Trisomy-21, 220
Tuberculin PPD, 315
Tuberculosis, 271
Tumour, 139
Tumour bearing rats, 371
Tumour necrosis serum, 293
Tumours
  I, 358
  II, 365
Tunicamycin, 234

VEP13, 703
Vaccination, *in vivo*, 564
Viral infections
  TIa$^+$ cells, 671
  polymorphonuclear cells, 265

X linked hypogammaglobulinaemia, 149

Zinc, 149